ABCD1 and X-linked adrenoleukodystrophy: These data confirm the previous observation that SAHA crosses the blood-brain barrier [79] and provides first preclinical proof-of-concept that SAHA is able to lower the VLCFA levels in CNS of Abcd1-KO mice, the target tissue in human X-ALD pathology.